Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study by Simone Parisi, Andrea Becciolini, Maria Chiara Ditto, Davide Rozza, Anna Zanetti, Angela Laganà, Clara Lisa Peroni, Chiara Centanaro Di Vittorio, Rosanna Degiovanni, Cristina Realmuto, Carlo Alberto Scirè, Marta Priora, Eleonora Di Donato, Daniele Santilli, Flavio Mozzani, Gianluca Lucchini, Alarico Ariani, Lucia Gardelli, Francesco Girelli, Eugenio Arrigoni, Ilaria Platè, Elena Bravi, Marino Paroli, Rosalba Caccavale, Carlo Salvarani, Gilda Sandri, Federica Lumetti, Alessandro Volpe, Antonio Marchetta, Enrico Fusaro

“…We evaluated the 3-year drug survival and efficacy of the biosimilar SB4/Benepali in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients, previously treated with etanercept (ETA). …”
Get full text

Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network by Ronald F van Vollenhoven, Bente Glintborg, Merete Lund Hetland, Ulf Lindström, Brigitte Michelsen, Elsa Vieira-Sousa, Florenzo Iannone, Eirik Klami Kristianslund, Dan Nordström, Karel Pavelka, Ziga Rotar, Maria Jose Santos, Catalin Codreanu, Gary J Macfarlane, Mikkel Østergaard, Michael T Nurmohamed, Jiri Vencovsky, Rosario Foti, Bjorn Gudbjornsson, Matija Tomšič, Lykke Midtbøll Ørnbjerg, Adrian Ciurea, Árni Jón Geirsson, Irene van der Horst-Bruinsma, Michael S Nissen, Ovidiu Rotariu, Isabel Castrejón, Johan K Wallman, Marleen van de Sande, Anne G Loft, Pasoon Hellamand, Thomas Klausch, Anna Mari Hokkanen, Corina Mogosan, Lucia Otero-Varela, Semih Gulle, Berrin Zengin

“…The primary outcome was clinically important improvement (CII) at 6 months according to Ankylosing Spondylitis Disease Activity Score with C-reactive protein (CRP) (≥1.1 decrease). …”
Get full text

Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy by Kauzar Mohamed Mohamed, María Paula Álvarez-Hernández, Carlos Jiménez García, Kissy Guevara-Hoyer, Dalifer Freites, Cristina Martínez Prada, Inés Pérez-Sancristóbal, Benjamín Fernández Gutiérrez, Gloria Mato Chaín, Maria Rodero, Antonia Rodríguez de la Peña, Teresa Mulero, Cecilia Bravo, Esther Toledano, Esther Culebras López, Beatriz Mediero Valeros, Pedro Pérez Segura, Silvia Sánchez-Ramón, Gloria Candelas Rodríguez

“…Results: Samples were obtained from 79 IMRD patients (51 women, 28 men; mean age 57 ± 11.3 years old): 43 rheumatoid arthritis, 10 psoriatic arthritis, 14 ankylosing spondylitis, 10 undifferentiated spondyloarthritis, and 2 inflammatory bowel disease-associated spondyloarthritis (IBD-SpA). …”
Get full text

Characterisation of cardiovascular involvement in inflammatory arthropathies and systemic rheumatic diseases using multi-parametric cardiovascular magnetic resonance by Ntusi, N, Ntobeko Ntusi

“…Hence, the aims of this D.Phil project were to (i) utilise CMR and MRS to study disease mechanisms in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), and (ii) to assess the role of anti-cytokine therapies in abrogation of cardiovascular complications and effects on cardiovascular function in patients with RA, ankylosing spondylitis (AS) and psoriatic arthritis (PsA).</p> <p>First, we used CMR to assess myocardial structure and function in RA, SLE and SSc patients with no known cardiovascular symptoms. …”

Enthesitis in patients with psoriatic arthritis: A nationwide data from the Chinese Registry of Psoriatic Arthritis (CREPAR) by Fan Yang, Chaofan Lu, Huilan Liu, Lei Dou, Yanhong Wang, Hongbin Li, Xinwang Duan, Lijun Wu, Yongfu Wang, Xiuying Zhang, Jian Xu, Jinmei Su, Dong Xu, Jiuliang Zhao, Qingjun Wu, Mengtao Li, Xiaomei Leng, Xiaofeng Zeng, Lishao Guo

“…Enthesitis was assessed by the Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht ankylosing spondylitis enthesitis score (MASES), and Leeds enthesitis index (LEI) indices. …”
Get full text

Experimental and genetic evidence for the impact of CD5 and CD6 expression and variation in inflammatory bowel disease by Sergi Casadó-Llombart, María Velasco-de Andrés, Cristina Català, Alejandra Leyton-Pereira, Rebeca Gutiérrez-Cózar, Belén Suárez, Noelia Armiger, Esther Carreras, Miriam Esteller, Miriam Esteller, Miriam Esteller, Elena Ricart, Elena Ricart, Elena Ricart, Ingrid Ordás, Ingrid Ordás, Ingrid Ordás, Javier P. Gisbert, Javier P. Gisbert, María Chaparro, María Chaparro, María Esteve, María Esteve, Lucía Márquez, David Busquets, Eva Iglesias, Eva Iglesias, Esther García-Planella, María Dolores Martín-Arranz, Juliane Lohmann, C. Korcan Ayata, Jan Hendrik Niess, Jan Hendrik Niess, Pablo Engel, Pablo Engel, Julián Panés, Julián Panés, Julián Panés, Azucena Salas, Azucena Salas, Azucena Salas, Eugeni Domènech, Eugeni Domènech, Francisco Lozano, Francisco Lozano, Francisco Lozano, ENEIDA Project of GETECCU, Alfredo J. Lucendo, Jordi Guardiola, Xavier Calvet, Lorenzo Olivá́n, Marta Piqueras

“…Regarding CD6, association was observed with CD ileal location (rs17824933G) and poor prognosis (rs12360861G), and with left-sided or extensive UC, and absence of ankylosing spondylitis in IBD (rs17824933G). The present experimental and genetic evidence support a role for CD5 and CD6 expression and variation in IBD’s clinical manifestations and therapeutic requirements, providing insight into its pathophysiology and broadening the relevance of both immunomodulatory receptors in immune-mediated disorders.…”
Get full text